Onconetix Provides $2.5M Bridge Loan to Realbotix

Onconetix has extended a $5 million bridge financing facility to its pending acquisition target, Realbotix LLC. This includes an immediate $2.5 million cash injection to support the subsidiary's operations and working capital. The move provides interim liquidity to the robotics firm while the companies await final regulatory and shareholder approvals for their planned all-stock acquisition.

According to an 8-K filing with the SEC, the facility is structured to integrate into the final deal terms. The loan is non-interest bearing if the acquisition successfully closes. Upon closing, the facility will be cancelled, and the total cash consideration required from Onconetix will be reduced by the principal amount advanced plus an additional $500,000.

Contingency Terms and Interest Penalties

The bridge agreement includes specific protections if the acquisition fails to materialize. If the Share Exchange Agreement is terminated, the loan terms change. The outstanding principal will begin to accrue interest at a rate of 12% per annum, calculated from the date of the termination.

This structure supports Realbotix's operations and acts as a financial hedge for Onconetix. By tying the repayment to the closing adjustments of the deal, the parent company ensures that the capital provided during the interim period is accounted for within the final valuation of the transaction.

Market Context and Deal Status

The acquisition of 100% of Realbotix remains subject to closing conditions, including formal approval from Onconetix shareholders and various regulatory bodies. As of September 16, 2026, Onconetix (ONCO) stock was trading at $0.69.

For investors, the bridge loan highlights the liquidity needs of the target company during the regulatory review process. The arrangement allows Realbotix to continue operations without seeking external capital that could complicate the existing share-exchange terms or dilute the equity stake being acquired by Onconetix.